Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Kroe-Barrett

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Bioanalysis|February 17, 2018
Optimizing NBE PK/PD assays using the Gyrolab Affinity Software; conveniently within the bioanalyst's existing workflowMaria Myzithras, Tammy Bigwarfe, Erica Waltz, et al.
Frontiers in Immunology|August 15, 2022
Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interactionSven Mostböck, Helen Haixia Wu, Timothy Fenn, et al.
Protein Science : a Publication of the Protein Society|April 12, 2018
Weak IgG self- and hetero-association characterized by fluorescence analytical ultracentrifugationDanlin Yang, John J Correia, Walter F Stafford Iii, et al.
Journal of Pharmaceutical Sciences|June 27, 2022
Effect of the ADCC-Modulating Mutations and the Selection of Human IgG Isotypes on Physicochemical Properties of FcHelen Haixia Wu, Maureen Crames, Yangjie Wei, et al.
Mabs|September 11, 2018
Non-neutralizing antibodies increase endogenous circulating Ang1 levelsChao Zheng, Joshuaine Toth, Tammy Bigwarfe, et al.
Biochemical and Biophysical Research Communications|August 22, 2018
Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodiesSathyadevi Venkataramani, Sarah Low, Bernd Weigle, et al.
Human Antibodies|December 2, 2011
Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activityPatricia Giblin, Rainer Boxhammer, Sudha Desai, et al.
Mabs|August 9, 2017
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRnDanlin Yang, Craig Giragossian, Steven Castellano, et al.
International Journal of Pharmaceutics|October 8, 2021
An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseasesHelen Haixia Wu, Kerry-Leigh Ralph, Eliud Sepuldeva, et al.
Mabs|January 12, 2020
VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosisSarah Low, Haixia Wu, Kavita Jerath, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Bioanalysis|February 17, 2018
Optimizing NBE PK/PD assays using the Gyrolab Affinity Software; conveniently within the bioanalyst's existing workflowMaria Myzithras, Tammy Bigwarfe, Erica Waltz, et al.
Frontiers in Immunology|August 15, 2022
Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interactionSven Mostböck, Helen Haixia Wu, Timothy Fenn, et al.
Protein Science : a Publication of the Protein Society|April 12, 2018
Weak IgG self- and hetero-association characterized by fluorescence analytical ultracentrifugationDanlin Yang, John J Correia, Walter F Stafford Iii, et al.
Journal of Pharmaceutical Sciences|June 27, 2022
Effect of the ADCC-Modulating Mutations and the Selection of Human IgG Isotypes on Physicochemical Properties of FcHelen Haixia Wu, Maureen Crames, Yangjie Wei, et al.
Mabs|September 11, 2018
Non-neutralizing antibodies increase endogenous circulating Ang1 levelsChao Zheng, Joshuaine Toth, Tammy Bigwarfe, et al.
Biochemical and Biophysical Research Communications|August 22, 2018
Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodiesSathyadevi Venkataramani, Sarah Low, Bernd Weigle, et al.
Human Antibodies|December 2, 2011
Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activityPatricia Giblin, Rainer Boxhammer, Sudha Desai, et al.
Mabs|August 9, 2017
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRnDanlin Yang, Craig Giragossian, Steven Castellano, et al.
International Journal of Pharmaceutics|October 8, 2021
An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseasesHelen Haixia Wu, Kerry-Leigh Ralph, Eliud Sepuldeva, et al.
Mabs|January 12, 2020
VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosisSarah Low, Haixia Wu, Kavita Jerath, et al.
Pageof 3